Share on Facebook
Share on Twitter
Share on LinkedIn

One of the nation’s leading cancer centers will no longer offer Zantac and its generics to patients, as it reviews the potential cancer risk from the discovery of a carcinogen in the popular stomach pills.

Memorial Sloan Kettering Cancer Center is removing Zantac products from the list of drugs that it offers patients “out of caution due to a recent product alert from the Food and Drug Administration,” Caitlin Hool, a spokeswoman for the New York-based center, said in an email on Monday. The process will take a few weeks, she said.

Read More